



PRESS RELEASE

FOR IMMEDIATE RELEASE

Monash grants license for Tocotrienol Prodrug platform to Invictus Biotechnology

Melbourne Victoria (6 March 2018) – Invictus Biotechnology Pty. Ltd., a private Australian biotechnology company developing and commercialising evidence-based nutraceuticals and pharmaceuticals based on a natural product (tocotrienols), today announced that it has been granted the exclusive global rights to exploit a new drug delivery technology platform for tocotrienols (Tocotrienol Prodrugs) developed by the Monash Institute of Pharmaceutical Sciences (MIPS).

The novel Tocotrienol Prodrug Platform is expected to deliver tocotrienols more effectively from the gut to target tissues and organs, without first passing through the liver. It has the potential to improve bioavailability, which could in turn, improve the utility of tocotrienols in a range of indications such as hyperlipidaemia, cancer and cardiac fibrosis. The prodrug platform was developed by Professor Chris Porter's research group at MIPS.

Invictus Biotechnology's Executive Chairman, Dr. Glenn Tong, said:

"This license from Monash University (which is globally recognised for its medical and drug discovery research), has the potential to add considerable value to our prescription medicines development program. The Porter group has a commendable track record in this field, so we are very excited about taking this technology forward with tocotrienols."

Invictus Biotechnology, working in collaboration with its research partners, will next assess the bioavailability and efficacy of these new analogues in animal models. The aim is to prepare for first in human clinical studies within the next 18-24 months.

**Investor and Media Enquiries:**

Dr. Douglas Pretsell, Investor and Media Relations
Ph: +61 (0) 409 908 553

Corporate enquiries:

Dr. Glenn Tong, Executive Chairman
Ph: +61 (0) 412 193 350

About Invictus Biotechnology

Invictus Biotechnology Pty. Ltd. is a private Australian biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, hyperlipidaemia, hypertension and diabetes. Invictus Biotechnology owns and controls patent and other intellectual property rights for novel approaches to delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

About the Monash Institute of Pharmaceutical Sciences

Monash University is one of Australia's premier scientific, health and medical universities and is consistently ranked among the leading universities in the world. The Monash Institute of Pharmaceutical Sciences (MIPS) has over 240 scientists and 180 PhD students that undertake basic and translational drug discovery, drug delivery and drug development research in new, state-of-the-art laboratories on Monash's Parkville campus. MIPS was established in 2008 and builds upon the ground-breaking research activities of the Victorian College of Pharmacy, Monash University, developers of the Relenza flu treatment. It is Australia's largest, most experienced and successful group of pharmaceutical scientists located near the Melbourne Biomedical Precinct in Parkville, on the edge of Melbourne's CBD. This precinct has established itself as a leading global research and teaching powerhouse and one of the top-five biomedical precincts in the world.